Lymphoma News

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with relapsed or refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial.

Pre-transplant immune checkpoint inhibitors extended survival for patients with relapsed classic Hodgkin lymphoma compared with chemotherapy, according to results of a retrospective study.

SAN DIEGO — Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented at ASH Annual Meeting and Exposition. Patients with commercial insurance and Medicaid had prescriptions rejected more often than patients with Medicare.

Glucarpidase significantly improved kidney function for patients who developed acute kidney injury from high-dose methotrexate, according to results of a large, multicenter observational study.

The FDA approved two oncology regimens on Jan. 16.

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.

Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.

SAN DIEGO — Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings achieved worse survival outcomes than those who received the agents in pivotal trials.